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INTRODUCTION
Antifungal susceptibility tests are performed on
fungi that cause disease, especially if they belong
to a species exhibiting resistance to commonly
used antifungal agents. Antifungal susceptibility
testing is also important for resistance surveil-
lance, for epidemiological studies and for
comparing the in-vitro activity of new and exist-
ing agents.
Dilution methods are used to establish the
MICs of antimicrobial agents. These are the
reference methods for antimicrobial susceptibility
testing, and are used mainly to establish the
activity of a new antifungal agent, to conﬁrm the
susceptibility of organisms that give equivocal
results in routine tests, and to determine the
susceptibility of fungi where routine dilution tests
may be unreliable. Fungi are tested for their
ability to produce visible growth in microdilution
plate wells containing broth culture media and
serial dilutions of the antifungal agents (broth
microdilution). The MIC is deﬁned as the lowest
concentration (in mg ⁄L) of an antifungal agent
that inhibits the growth of a fungus. The MIC
provides information concerning the susceptibil-
ity or resistance of an organism to the antifungal
agent and can help in making correct treatment
decisions.
The method described in this document is
intended for testing the susceptibility of
yeasts that cause clinically signiﬁcant infections
(primarily Candida spp.). The method encom-
passes only those yeasts that are able to ferment
glucose. Thus, the susceptibility of non-fermenta-
tive yeasts, e.g., Cryptococcus neoformans, cannot
be determined by the current procedure, and the
method is not suitable for testing the yeast forms
of dimorphic fungi.
SCOPE
The standard method described in this document
provides a valid method for testing the suscepti-
bility of glucose-fermenting yeasts to antifungal
agents by determination of the MIC. MICs indi-
cate the activity of a given antifungal drug under
the described test conditions, and can be used in
making decisions concerning patient manage-
ment after taking into account other factors, e.g.,
pharmacokinetics, pharmacodynamics and resis-
tance mechanisms. The MIC also allows fungi to
be categorised as ‘susceptible’ (S), ‘intermediate’
(I) or ‘resistant’ (R) to a drug. In addition, MIC
distributions can be used to deﬁne wild-type or
non-wild-type fungal populations.
This method is intended primarily to facilitate
an acceptable degree of conformity, i.e., agree-
ment within speciﬁed ranges among laboratories,
in measuring the susceptibility of yeasts to anti-
fungal agents. The method is designed to be easy
to perform, rapid, economical, and suitable for
reading by microdilution plate readers in order to
allow direct transfer, storage and manipulation of
the data by computer. The method is also
intended to yield results that are concordant
with those obtained using the procedure
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recommended by CLSI document M27 for anti-
fungal susceptibility testing of yeasts [1].
TERMS AND DEFINITIONS
Antifungal agent
An antifungal agent is a substance of biological,
semi-synthetic or synthetic origin that inhibits the
growth of fungi or is lethal to them. Disinfectants,
antiseptics and preservatives are not included in
this deﬁnition.
Potency
Potency is the antimicrobially active fraction of a
test substance, determined in a bioassay against a
reference powder of the same substance. The
potency is expressed as mass fraction in mg ⁄ g, or
as activity content in International Units (IU) ⁄g,
or as a volume fraction or mass fraction in
per cent, or as an amount-of-substance concen-
tration (mass fraction) in mol ⁄L of the ingredients
in the test substance.
Concentration
Concentration is the amount of an antimicrobial
agent in a deﬁned volume of liquid. The concen-
tration is expressed in SI units as mg ⁄L. Although
mg ⁄L is equivalent to lg ⁄mL, the use of the latter
is not recommended.
Stock solution
A stock solution is an initial solution used for
additional dilutions.
MIC
The MIC is the lowest concentration of a substance
that inhibits the growth of fungi within a deﬁned
period of time. The MIC is expressed in mg ⁄L.
Breakpoint
Breakpoints are speciﬁc MIC values that enable
fungi to be assigned to the clinical categories
‘susceptible’, ‘intermediate’ and ‘resistant’. Break-
points can be altered according to changes in
circumstances (e.g., changes in commonly used
drug dosages).
Susceptible (S). A fungal strain inhibited in vitro by
a concentration of an antifungal agent that is
associated with a high likelihood of
therapeutic success. Fungi are categorised as
susceptible by applying the appropriate
breakpoints in a deﬁned phenotypic test system.
Intermediate (I). A fungal strain inhibited in vitro
by a concentration of an antifungal agent that is
associated with a doubtful therapeutic effect.
Fungal strains are categorised as intermediate
by applying the appropriate breakpoints in a
deﬁned phenotypic test system. Intermediate
susceptibility implies that an infection caused
by the isolate can be treated effectively at body
sites where the antifungal drug is physiologi-
cally concentrated or when a high dosage of
drug can be used. This class also includes a
‘buffer zone’, to prevent small, uncontrolled,
technical factors from causing major
discrepancies in interpretations.
Resistant (R). A fungal strain inhibited in vitro by a
concentration of an antimicrobial agent that is
associated with a high likelihood of therapeutic
failure. Fungal strains are categorised as resistant
by applying the appropriate breakpoints in a
deﬁned phenotypic test system.
Wild-type
The term ‘Wild-type’ refers to an isolate without
acquired resistance mechanisms to the antifungal
agent.
Control strain
The term ‘Control strain’ refers to a catalogued,
characterised strain with stable, deﬁned antifun-
gal susceptibility phenotypes and ⁄ or genotypes.
Such strains are obtainable from culture collec-
tions and are used for quality control purposes.
Broth dilution
Broth dilution is a susceptibility testing technique
in which serial dilutions (usually two-fold) of an
antifungal agent are made in a liquid medium
that is inoculated with a standardised number of
organisms and incubated for a prescribed period.
The objective of this method is the determination
of the MIC.
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Broth microdilution
The performance of broth dilution in microdilu-
tion plates containing wells with a nominal
capacity of c. 300 lL ⁄well is referred to as ‘broth-
microdilution’.
Broth
The term ‘broth’ refers to the ﬂuid medium used
for the in-vitro growth of fungi.
Inoculum
The number of yeasts (CFU) in a deﬁned volume.
The inoculum is expressed as CFU ⁄mL.
TEST PROCEDURES
The test is performed in microdilution plates. The
method is based on the preparation of working
solutions of antifungal agents in 100-lL vol-
umes ⁄well (with the addition of an inoculum
also in a volume of 100 lL).
Medium
A completely synthetic medium, RPMI-1640 sup-
plemented with glutamine and a pH indicator, but
without bicarbonate, has been recommended [2,3].
However, RPMI-1640 (Table 1) contains only 2 g
glucose ⁄L (0.2% w ⁄v), a concentration that is lower
than that used commonly for culturing yeasts.
Supplementing medium to a ﬁnal concentration of
20 g glucose ⁄L (2% w ⁄v) has been shown to result
in better growth of yeast isolates without altering
the MICs of antifungal agents markedly [4].
Zwitterion buffers are preferred to Tris, which
antagonises the activity of ﬂucytosine, and also to
phosphate buffer, which may give unexpected
interactions with antifungal agents. The buffer
3-(N-morpholino)-propanesulphonic acid (MOPS),
used at a ﬁnal concentration of 0.165 mol ⁄L, pH 7.0,
is satisfactory for RPMI-1640 media. The recom-
mended medium, RPMI containing glucose
2% w ⁄v (RPMI-1640 2% G), ispreparedas follows:
1 Add the components listed in Table 2 to
900 mL of distilled water.
2 Stir until components are completely dissolved.
3 With stirring, adjust the pH to 7.0 at 25C with
1 M sodium hydroxide.
4 Add water to a ﬁnal volume of 1 L.
5 Filter sterilise using a 0.22-lm ﬁlter.
6 Store at 4C.
7 For quality control purposes, use one aliquot of
the sterilised medium for sterility checks, for
retesting the pH (6.9–7.1 is acceptable), and as a
growth control with a reference strain.
Medium for testing amphotericin B
No speciﬁc medium can currently be recommen-
ded for testing susceptibility to amphotericin B.
Table 1. Composition of RPMI-1640
Constituent g ⁄L
L-Arginine (free base) 0.200
L-Asparagine (anhydrous) 0.050
L-Aspartic acid 0.020
L-Cystine.2HCl 0.0652
L-Glutamic acid 0.020
L-Glutamine 0.300
Glycine 0.010
L-Histidine (free base) 0.015
L-Hydroxyproline 0.020
L-Isoleucine 0.050
L-Leucine 0.050
L-Lysine.HCl 0.040
L-Methionine 0.015
L-Phenylalanine 0.015
L-Proline 0.020
L-Serine 0.030
L-Threonine 0.020
L-Tryptophan 0.005
L-Tyrosine, 2Na 0.02883
L-Valine 0.020
Biotin 0.0002
D-Pantothenic acid 0.00025
Choline chloride 0.003
Folic acid 0.001
Myo-inositol 0.035
Niacinamide 0.001
Para-amino benzoic acid 0.001
Pyridoxine.HCl 0.001
Riboﬂavin 0.0002
Thiamin.HCl 0.001
Vitamin B12 0.000005
Calcium nitrate.H2O 0.100
Potassium chloride 0.400
Magnesium sulphate (anhydrous) 0.04884
Sodium chloride 6.000
Sodium phosphate, dibasic (anhydrous) 0.800
D-Glucosea 2.000
Glutathione, reduced 0.001
Phenol red, Na 0.0053
aNote that this medium contains glucose 0.2% w ⁄ v and not the recommended
concentration of 2% w ⁄ v.
Table 2. Components of RPMI-1640 2% G
Component 1· concentration 2· concentration
Distilled water 900 mL 900 mL
RPMI-1640a 10.4 g 20.8 g
MOPS 34.53 g 69.06 g
Glucose 18 g 36 g
aSee Table 1.
MOPs, 3-(N-morpholino) propanesulphonic acid.
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Hence, for the time being, it is recommended
that the same method used for ﬂucytosine,
azole drugs and echinocandins be adopted for
amphotericin B. The non-synthetic broth Anti-
biotic Medium 3 (AM3), supplemented to a ﬁnal
concentration of glucose 2% w ⁄v, has been eval-
uated for detecting resistance to amphotericin B
[5–8]. However, there is batch-to-batch variation
in this medium, and also in the performance
of the medium from different manufacturers.
Preliminary results indicate that an inoculum of
0.5–2.5 · 105 CFU ⁄mL is too large for testing
susceptibility to amphotericin B in AM3 [5].
ANTIFUNGAL AGENTS
All antifungal drug solutions should be prepared
in accordance with Good Manufacturing Practice.
Antifungal powders must be obtained directly
from the drug manufacturer or from reliable
commercial sources. Clinical preparations must
not be used, not least because they often contain
excipients that may interfere with susceptibility
testing. Powders must be supplied with the
generic name of the drug, a lot number, potency,
expiry date and recommended storage condi-
tions. Powders should be stored in sealed con-
tainers at )20C or below with a desiccant unless
otherwise recommended by the manufacturer.
Ideally, hygroscopic agents should be dispensed
into aliquots, one of which is used on each
occasion. Containers should be allowed to warm
to room temperature before opening in order to
avoid condensation of water on the powder.
Preparation of stock solutions
Antifungal drug solutions must be prepared after
taking the potency of the lot of antifungal drug
powder into account. The amount of powder or
diluent required to prepare a standard solution
may be calculated as follows:
WeightðgÞ ¼ VolumeðLÞ  Concentrationðmg=LÞ
Assay potencyðmg=gÞ
VolumeðLÞ ¼WeightðgÞ Assaypotencyðmg=gÞ
Concentrationðmg=LÞ
Weigh the antifungal drug powder on an
analytical balance that has been calibrated to
two decimal places when weighing 100 mg. It is
recommended that at least 100 mg of powder is
weighed. Prepare antifungal drug stock solu-
tions at concentrations 200-fold greater than the
highest concentration to be tested. Information
on the solubility of antifungal compounds
should be provided by the supplier. Solvents
other than water are required to dissolve some
antifungal drugs (Table 3). Sterilisation of stock
solutions is not normally necessary, but mem-
brane ﬁltration should be used if required.
Other ﬁlter materials are best avoided, as they
may adsorb signiﬁcant amounts of drug. When
ﬁltration is used, samples must be obtained
before and after ﬁltration, and must be assayed
to ensure that the drug is not adsorbed to the
ﬁlter. Unless otherwise indicated by the drug
manufacturer, store drug solutions in small
volumes in sterile polypropylene or polyethyl-
ene vials at )70C or below. Drugs other than
echinocandins may be stored at )70C for at
least 6 months without signiﬁcant loss of activ-
ity [9]. Echinocandins are unstable, so stock
solutions must not be kept for >2 months at
)70C. Remove vials from )70C storage and
use them on the same day that they are
defrosted. Discard any drug not used on that
day. Signiﬁcant deterioration of an antifungal
drug will be reﬂected in the results of testing
the susceptibility of quality control strains. If
necessary, the drug can be assayed to determine
the potency.
Preparation of working solutions
The range of concentrations tested will depend on
the organism and the antifungal drug being
tested. The range of concentrations should
encompass the breakpoint, if one exists, as well
Table 3. Solvents for preparation of stock solutions,
together with characteristics and appropriate test concen-
tration ranges for antifungal agents
Antifungal agent Solvent Characteristics Test range (mg ⁄L)
Amphotericin B DMSO Hydrophobic 0.0312–16
Fluconazole Water Hydrophilic 0.125–64
Itraconazole DMSO Hydrophobic 0.0156–8
Voriconazole DMSO Hydrophobic 0.0156–8
Posaconazole DMSO Hydrophobic 0.0156–8
Flucytosine Water Hydrophilic 0.125–64
Caspofungin Water Hydrophilic 0.0312–16
Micafungin Water Hydrophilic 0.0312–16
Anidulafungin DMSO Hydrophobic 0.0312–16
DMSO, dimethylsulphoxide.
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as the expected results for the quality control
strains. The drug concentration ranges in Table 3
are recommended. A two-fold dilution series
based on 1 mg ⁄L is prepared in double-strength
RPMI-1640 2% G. The RPMI-1640 2% G used in
plates is prepared at double the ﬁnal strength to
allow for a 50% dilution following addition of the
inoculum. This approach allows the inoculum to
be prepared in distilled water.
Dilutions should be prepared according to ISO
recommendations [10]. Alternative dilution
schemes may be used if they are shown to
perform as well as the reference method. For
example, an alternative method that uses smaller
volumes to prepare a dilution series with ﬁnal
concentrations of 0.125–64 mg ⁄L is shown in
Table 4 (see Table 3 to check the solvents required
for each antifungal agent). A summary of the
steps required to prepare working solutions
(2 · ﬁnal concentration) in this alternative scheme
is as follows:
1 Take an antifungal drug stock tube from the
)70C freezer.
2 Dispense the appropriate volumes of solvent
(consult Table 3 for solvents and Table 4 for
volume of solvents) into nine further tubes.
3 Follow the steps described in Table 4 to pro-
duce a dilution series at 200-fold the ﬁnal
concentration. Similar dilution schemes with a
stock concentration of 3200 mg ⁄L or 1600 mg ⁄L
in step 1 of Table 4 are required for dilution
series of 0.03–16 mg ⁄L and 0.015–8 mg ⁄L,
respectively.
4 Dispense 9.9 mL of double-strength RPMI-
1640 2% G into ten tubes.
5 Take 100 lL from each of the tubes with
200 · ﬁnal concentration of antifungal drug in
solvent and transfer to the ten tubes with
9.9 mL of culture medium (1:100 dilution).
The concentration of solvent in the culture
medium tubes is 1% and the concentration of
antifungal agent is 2 · ﬁnal concentration.
Preparation of microdilution plates
Use sterile plastic, disposable, 96-well micro-
dilution plates with ﬂat-bottomed wells that
have a nominal capacity of c. 300 lL. For the
wells in each column, from 1–10, of the micro-
dilution plate, dispense 100 lL from each of the
tubes containing the corresponding concentra-
tion (2 · ﬁnal concentration) of antifungal agent.
For example, with itraconazole, voriconazole or
posaconazole, dispense to column 1 the medium
containing 16 mg ⁄L, to column 2 the medium
containing 8 mg ⁄L, and so on to column 10 for
the medium containing 0.03 mg ⁄L. To each well
in columns 11 and 12, dispense 100 lL of
double-strength RPMI-1640 2% G. Thus, each
well in columns 1–10 will contain 100 lL of
twice the ﬁnal antifungal drug concentrations
in double-strength RPMI-1640 2% G with 1%
solvent.
Storage of microdilution plates
The plates can be sealed in plastic bags or
aluminium foil and stored frozen at )70C or
below for up to 6 months, or at )20C for not
more than 1 month, without loss of drug potency.
Once plates are defrosted, they must not be
refrozen. Echinocandins are unstable, so the
prepared trays must be stored at )70C or below
for no more than 2 months.
Table 4. Scheme for preparing dilution series of antifungal agents with a ﬁnal concentration of 0.125–64 mg ⁄L
Step
Concentration
(mg ⁄L) Source
Volume of
antifungal (lL)
Volume of
solventa (lL)
Intermediate
concentration (mg ⁄L)
Concentration (mg ⁄L)
after 1:100 dilution with
double-strength RPMI-1640 2% Gb
1 12 800c Stock 200 0 12 800 128
2 12 800 Stock 100 100 6400 64
3 12 800 Stock 50 150 3200 32
4 12 800 Stock 50 350 1600 16
5 1600 Step 4 100 100 800 8
6 1600 Step 4 50 150 400 4
7 1600 Step 4 50 350 200 2
8 200 Step 7 100 100 100 1
9 200 Step 7 50 150 50 0.5
10 200 Step 7 25 175 25 0.25
aConsult Table 3 for solvents required to make dilutions of antifungal agents.
bDilution 1:1 with inoculum suspension gives ﬁnal concentrations half those indicated.
cFor dilution series with highest ﬁnal concentrations of 16 mg ⁄L or 8 mg ⁄L, start with stock concentrations of 3200 mg ⁄L and 1600 mg ⁄L, respectively.
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PREPARATION OF INOCULUM
Standardisation of the inoculum is essential for
accurate and reproducible antifungal susceptibil-
ity tests. The inoculum should be prepared by
suspending ﬁve representative colonies, obtained
from an 18–24-h culture on non-selective nutritive
agar medium, in sterile distilled water. The ﬁnal
inoculum must be between 0.5 · 105 and
2.5 · 105 CFU ⁄mL.
Colony suspension method
1 Culture all yeasts in ambient air at 35 ± 2C on
non-selective nutritive agar medium (Sabou-
raud’s dextrose agar or potato dextrose agar)
for 18–24 h before testing.
2 Prepare the inoculum by suspending ﬁve
distinct colonies, ‡1 mm in diameter from
24 h cultures, in 5 mL of sterile distilled
water.
3 Evenly suspend the inoculum by vigorous
shaking on a vortex mixer for 15 s. Adjust the
cell density to the density of a 0.5· McFarland
standard (Table 5) by measuring the absor-
bance in a spectrophotometer at a wavelength
of 530 nm and adding sterile distilled water as
required. This will give a yeast suspension of
1–5 · 106 CFU ⁄mL. Prepare a working suspen-
sion from a 1 in 10 dilution of the standardised
suspension in sterile distilled water to yield
1–5 · 105 CFU ⁄mL.
INOCULATION OF MICRODILUTION
PLATES
The microdilution plates should be inoculated
within 30 min of preparing the inoculum suspen-
sion in order to maintain the viable cell concen-
tration. Inoculate each well of a microdilution
plate with 100 lL of the 1–5 · 105 CFU ⁄mL yeast
suspension. This will give the required ﬁnal drug
concentration and inoculum density (ﬁnal inocu-
lum = 0.5–2.5 · 105 CFU ⁄mL). Also inoculate the
growth control wells (column 11), containing
100 lL of sterile drug-free medium, with 100 lL
of the same inoculum suspension. Fill column 12
of the microdilution plate with 100 lL of sterile
distilled water from the lot used to prepare the
inoculum as a sterility control for medium and
distilled water (drug-free medium only). Test
quality control organisms by the same method
each time an isolate is tested. Viable counts
should be performed to ensure that test wells
contain between 0.5 · 105 and 2.5 · 105 CFU ⁄mL.
This should be done by removing 10 lL from the
growth control well immediately after inoculation
and diluting it in 2 mL of sterile distilled water.
The suspension is homogenised using a gyratory
vortex mixer at 2000 rpm, and 100 lL of the
resulting suspension is then spread over the
surface of a suitable agar plate, which is then
incubated for 24–48 h. An acceptable test suspen-
sion would yield 5–125 colonies. If this is not
achieved, the results for the isolate in question
cannot be used.
INCUBATION OF MICRODILUTION
PLATES
Incubate microdilution plates without agitation at
35 ± 2C in ambient air for 24 ± 2 h. An absor-
bance of £0.2 indicates poor growth and is seen
most commonly among strains of Candida parapsi-
losis and Candida guilliermondii. Such plates
should be re-incubated for a further 12–24 h and
then read again. Failure to reach an absorbance of
0.2 after 48 h constitutes a failed test.
READING RESULTS
The microdilution plates must be read with a
microdilution plate reader. The recommended
wavelength for measuring the absorbance of the
plate is 530 nm, although other wavelengths can
be used, e.g., 405 or 450 nm. The value of the
blank (background) should be subtracted from
the readings for the other wells.
Amphotericin B
The MIC of amphotericin B is the lowest concen-
tration giving rise to an inhibition of growth of
‡90% of that of the drug-free control.
Table 5. Preparation of 0.5·McFarland turbidity standard
Step Procedure
1 Add 0.5 mL of 0.048 mol ⁄L BaCl2 (1.175% w ⁄v BaCl2.2H2O) to 99.5 mL
of 0.18 mol ⁄L (0.18 M) H2SO4 1% v ⁄v and mix thoroughly
2 Check the density with a spectrophotometer having a 1-cm light path
and matched cuvettes. The absorbance at 530 nm should be 0.12–0.15
3 Distribute in screw-cap tubes of the same size as those used for test
inoculum adjustment
4 Store sealed standards in the dark at room temperature
5 Mix the standard thoroughly on a vortex mixer immediately before use
6 Renew standards or check their absorbance after storage for 3 months
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Flucytosine, azole antifungal agents and
echinocandins
The MIC of ﬂucytosine (5-ﬂucytosine), azole
antifungal drugs and echinocandins is the lowest
drug concentration giving rise to an inhibition of
growth of ‡50% of that of the drug-free control.
INTERPRETATION OF RESULTS
Interpretative breakpoints have yet to be estab-
lished for most antifungal agents, and the clinical
relevance of testing remains uncertain. EUCAST
has recommended breakpoints for ﬂuconazole
[11] (http://www.srga.org/eucastwt/MICTAB/
index.html) and is developing breakpoints for
other agents. CLSI has recommended breakpoints
for ﬂucytosine, ﬂuconazole, itraconazole and vo-
riconazole [1,12,13]. There are no available data
for echinocandins.
QUALITY CONTROL
Control procedures are the means by which the
quality of results is assured; these have been
described in detail by CLSI [1]. The routine
quality of test results is monitored by the use of
control strains.
Control strains
MICs for control strains should ideally be close
to the middle of the range of the two-fold series
tested, and antifungal drug susceptibility pat-
terns must be stable. The recommended control
strains shown in Table 6 were selected according
to these criteria [14,15]. Control strains should be
obtained from a reliable source, e.g., the Amer-
ican Type Culture Collection (ATCC), National
Collection for Pathogenic Fungi (NCPF), Central
Bureau for Schimmelcultures (CBS), or commer-
cial suppliers offering similar guarantees of
quality.
Storage of control strains
Yeasts may be stored lyophilised or frozen at
)60C or below [16]. Cultures can be stored in the
short-term on Sabouraud’s dextrose agar or
potato dextrose agar slopes at 2–8C, with new
cultures being prepared from frozen stocks every
2 weeks.
Routine use of control strains
For routine use of control strains, fresh cultures
on non-selective nutritive agar medium (e.g.,
Sabouraud’s dextrose agar or potato dextrose
agar) must be prepared from agar slopes, or
frozen or lyophilised cultures.
1 At least two control strains must be included
each day that the test is performed, and the
MICs should be within the control ranges
given in Table 6. If more than one in 20 tests
is out of range, the source of error must be
investigated.
2 Each test must include a well of medium
without antifungal drug to demonstrate
growth of the test organisms and provide a
turbidity control for reading endpoints.
3 Subculture inocula on suitable agar medium
(preferably a chromogenic medium) to ensure
purity and to provide fresh colonies if retesting
is required.
4 Test each new batch of medium, lot of micro-
dilution plates and lot of RPMI-1640 2% G
medium with at least two of the quality control
strains listed in Table 6 to ensure that MICs fall
within the expected range [17].
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